These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35533650)

  • 1. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
    Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
    Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; Aleskandarany MA; Alkawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1460-1472. PubMed ID: 31175327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Van Bockstal MR; Wesseling J; Lips EH; Smidt M; Galant C; van Deurzen CHM
    Breast Cancer Res; 2024 Aug; 26(1):125. PubMed ID: 39192322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
    Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
    J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
    Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
    Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
    Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
    Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
    J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
    Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.
    Lashen A; Alqahtani S; Shoqafi A; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.